| 2005-02-24: |
Zeltia: Report at 31 December 2004
Madrid, Spain ( PRN/ots ) - PharmaMar: - Yondelis: - Due to the good results presented at the ASCO ( American Society of Clinical Oncology ) meeting, the randomised pivotal trial on soft - tissue sarcoma was expanded so as to compile a dossier for a regulatory (...) |
| 2006-07-18: |
Novartis to Build Latest - Technology Influenza Vaccines Manufacturing Site in North Carolina
Basel, Switzerland ( PRN/ots ) - - Novartis Vaccines on track to be the first to manufacture new cell culture - derived influenza vaccines in the United States - New site to support pandemic preparedness - First submission of a cell culture - derived influenza vaccine (...) |
| 2005-06-15: |
Orion Diagnostica to Transfer Production From Oulunsalo to Turku
Espoo, Finland ( PRN/ots ) - Negotiations have been completed with the personnel representatives in Orion Diagnostica Oy, a subsidiary of Orion Corporation, concerning operational rearrangements at Orion Diagnostica's sites in Finland. As a result of the negotiations, a decision has been made to transfer the production (...) |
| 2007-08-29: |
AstraZeneca's Once - Daily SEROQUEL XR( TM ) Extended - Release Tablets Approved in Netherlands for the Acute and Long Term Treatment of Schizophrenia
London ( PRN/ots ) - - For International Medical Journalists Only AstraZeneca today announced the Netherlands regulatory authority MEB ( Medicines Evaluation Board ) has approved SEROQUEL XR( TM ) ( quetiapine fumarate ) Extended - Release Tablets, a once - daily medicine for the treatment of schizophrenia in adult patients. With SEROQUEL XR( TM ) (...) |
| 2008-04-10: |
Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide
Istanbul, Turkey ( PRN/ots ) - - Multi - national study will follow 60,000 women for 5 years Nearly 60,000 women aged 55 years and older have enrolled in a landmark, multi - national study that will focus on the management of osteoporosis across the globe. (...) |
| 2004-12-10: |
More Choice for More Women
San Antonio, Texas ( PRN/ots ) - - 'The Latest Hormonal Treatment Options in the Breast Cancer Continuum' - An AstraZeneca Sponsored Webcast From the 2004 San Antonio Breast Cancer Symposium This webcast will announce key new data for 'FASLODEX' and 'ARIMIDEX' that is being presented (...) |
| 2011-01-10: |
Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration
San Francisco, USA and Freising, Germany ( na Originaltextservice ) - Takeda San Francisco ( TSF ) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced (...) |
| 2006-04-20: |
Bridging Science and Art / Electroacoustic prelude to the informal EU Council meeting in Graz
Graz ( na Originaltextservice ) - - Cross reference: Picture is available free of charge at http://www.presseportal.de/galerie.htx?type=obs - "Poèmes Electroniques" on April 20 in Graz range from the sensorial experience of three - dimensional acoustics to the sound of a diesel engine (...) |
| 2009-08-03: |
The European Commission Approves Samsca( TM ) ( tolvaptan ), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion ( SIADH )
Tokyo, Japan and Uxbridge, England ( PRN/ots ) - Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. ( OPEL ) announced today that the European Commission has approved the Marketing Authorisation Application for the company's oral once - daily medication Samsca( TM )( tolvaptan ), a selective V2 - vasopressin receptor antagonist, for (...) |
| 2005-03-30: |
AEterna Zentaris Receives First Regulatory Approval for Impavido( R ) for Parasitic Skin Disease
Frankfurt, Germany ( na Originaltextservice ) - AEterna Zentaris Inc. ( TSX: AEZ; NASDAQ: AEZS ) announced it has received Colombian Food and Drug Agency approval for Impavido( R ) ( miltefosine ), to treat the cutaneous form of leishmaniasis, a severe parasitic skin disease estimated to affect millions of people worldwide. This is (...) |
| 2011-02-23: |
Sanofi Pasteur Supports Polio Eradication at First International Stock Exchange Event
LYON, France and SWIFTWATER, Pennsylvania, February 23, 2011 ( PRN/ots ) - - Sanofi Pasteur, the vaccines division of sanofi - aventis Group , today will participate in the first international bell - ringing event by a company listed on NYSE Euronext. The events will acknowledge past successes and (...) |
| 2009-08-31: |
Neuromuscular Disease Treatment Catena( R ) Available in Europe on a Named Patient Basis
Liestal, Switzerland and Weybridge, England ( PRN/ots ) - - - Santhera and Idis Partner to Facilitate Patient Access to Friedreich's Ataxia Drug Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases and Idis announced today that Catena( R ) will be made available on (...) |
| 2007-08-29: |
American Stock Exchange Accepts Callisto Pharamceuticals' Plan of Compliance and Extension to Regain Compliance with Standards
New York ( PRN/ots ) - Callisto Pharmaceuticals, Inc. ( Amex: KAL; FWB: CA4 ), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, today announced that the staff of the American Stock Exchange ( "AMEX" ) has reviewed the Company's plan (...) |
| 2006-03-17: |
Advisory - Isotechnika to Announce Clinical Data From Phase III Psoriasis Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. will announce preliminary 48 week clinical trial data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, on Monday, March 20th at 8:00 a.m. EST/6:00 a.m. MST. Management will (...) |
| 2010-01-07: |
Tolerx Completes Enrollment in DEFEND - 1, A Phase 3 Type 1 Diabetes Study With Otelixizumab
Cambridge, Massachusetts ( PRN/ots ) - Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND - 1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new - onset autoimmune type 1 diabetes. (...) |
| 2010-03-31: |
Cellvax Expands its Preclinical Service Offers by Moving to a New Laboratory Facility With an Access to Large Animals and a Number of New Technical Plat - Forms
Paris, March 31, 2010 ( PRN/ots ) - Cellvax is a French service company which provides complete in vitro & in vivo preclinical innovating services allowing to accelerate the drug development process for unmet needs related with severe human diseases, mainly in oncology field. Cellvax was (...) |
| 2004-10-06: |
FDA Grants Aplidin( R ) Orphan Drug Status for the Treatment of Multiple Myeloma
Madrid, Spain ( PRN/ots ) - PharmaMar announced today that Aplidin( R ), its second marine - derived compound in Phase II clinical development, has been granted orphan drug status by the United States ( US ) Food and Drug Administration ( FDA ), for the treatment of Multiple Myeloma ( MM ). This is (...) |
| 2005-09-07: |
New International Treatment Guidelines Verify Crucial Role of 'Arimidex'( TM ) ( Anastrozole ) for Postmenopausal Women With Early Breast Cancer
Macclesfield, England ( PRN/ots ) - Today, new guidelines from the prestigious St. Gallen 'International Consensus Conference on the Primary Therapy of Early Breast Cancer' were released ahead of publication on the Annals of Oncology website( 1 ). For the first time, the St. Gallen consensus panel has (...) |
| 2007-06-18: |
More Than Half of Hypertensive Patients Remain Uncontrolled and at Higher Risk of Heart Attack and Stroke - Telmisartan May Decrease This Risk
Milan, Italy ( PRN/ots ) - - For non - US Healthcare Media - Results From Two Large, Multinational, Practice - Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of Hypertension ( ESH ) show that measuring blood pressure in a doctor's office (...) |
| 2009-06-06: |
New Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results
Ingelheim, Germany ( PRN/ots ) - - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year's American Diabetes (...) |
| 2005-09-22: |
18th International Nutrition Congress - 'Are You Getting Enough?'
Durban, South Africa ( PRN/ots ) - Trusted name Knorr is breaking new ground with Knorr Vie Shot, a naturally delicious drink bursting with fruits and vegetables. This fruit and vegetable "booster shot" is a direct response to consumers' health needs. With its focus on (...) |
| 2005-04-28: |
Isotechnika Receives No Objection Letter From Health Canada for Phase IIb Kidney Transplant Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. This randomized, open - label trial will include approximately (...) |
| 2004-10-08: |
International Prix Galien 2004: Revolutionary HIV Drug Fuzeon Receives Most Prestigious Award for Innovation in Pharmaceutical Industry
Basel, Switzerland ( PRN/ots ) - Today, HIV drug Fuzeon ( enfuvirtide or T - 20 ) was awarded the 2004 International Prix Galien for the most innovative new medicine. Fuzeon was selected out of 12 major new drugs in all therapeutic areas which each won national awards. Since (...) |
| 2006-10-03: |
Isotechnika Receives European Patent for Lead Immunosuppressive Drug, ISA247
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. announced today that the Company has been issued European Patent No. EP0991660 for its lead immunosuppressive drug, ISA247. The patent entitled "DEUTERATED AND UNDEUTERATED CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS" is the ninth patent to be (...) |
| 2011-02-21: |
Nordion Signs Share Purchase Agreement to Divest MDS Nordion S.A.
Ottawa, Canada ( PRN/ots ) - Nordion Inc. , a leading provider of products and services to the global health science market, today announced it has signed a share purchase agreement ( SPA ) with Best Medical Belgium ( Best Medical ) for the divestiture of the Company's Belgian operations, (...) |
| 2011-01-17: |
Astellas Enters Into License Agreement With TOLMAR
Tokyo ( PRN/ots ) - Astellas Pharma Inc. announced today that its European subsidiary Astellas Pharma Europe Ltd.( "Astellas Pharma Europe", headquarters: Stains, U.K. )" acquired the license for commercialization of the treatment for advanced prostate cancer Eligard( R ) from TOLMAR Inc. ( "TOLMAR", headquarters: Colorado, U.S.A. ) on December 22, (...) |
| 2009-03-20: |
Another LNA - based RNA Inhibitor Enters Clinical Trials
Copenhagen ( PRN/ots ) - - EZN3042 - a Survivin Inhibitor Jointly Developed by Enzon Pharmaceuticals and Santaris Pharma Advances into the Clinic for Patients With Solid Tumors and Lymphomas Santaris Pharma announced today that the fourth LNA - based drug has been brought into the clinic. (...) |
| 2007-09-03: |
New Study Findings Confirm CLEXANE( R )/LOVENOX( R ) Long - Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Paris ( PRN/ots ) - Sanofi - aventis announced today that one year findings from the landmark ExTRACT - TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST - segment elevation myocardial infarction ( STEMI ) for Lovenox( R ) vs Unfractionnated Heparin ( UFH ). The ExTRACT - TIMI (...) |
| 2008-12-06: |
New Data From Largest - Ever Clinical Trials in CLL Show MabThera Enables Leukaemia Patients to Live Longer Without Their Disease Progressing
Basel, Switzerland ( PRN/ots ) - - For Non - US and Non - UK Media BASEL, Switzerland, December 6 /PRNewswire/ - - - Abstract Numbers: 325 & LBA - 1 BASEL, Switzerland, December 6 /PRNewswire/ - - - Pivotal Phase III Results Suggest MabThera is Set to Change the Face of (...) |
| 2006-01-19: |
Roche and Trimeris Announce Selection of Two Next Generation HIV Fusion Inhibitor Drug Candidates for Development
Basel, Switzerland and Morrisville, North Carolina ( PRN/ots ) - - Early Preclinical Data on TR - 291144 and TR - 290999 to be Presented at Major HIV Congress in February BASEL, Switzerland and MORRISVILLE, North Carolina, January 19 /PRNewswire/ - - Roche and Trimeris today announced their (...) |
| 2008-09-22: |
Axxonis Pharma AG, has identified and patented several new chemical entities as neuroprotective agents
Berlin ( na Originaltextservice ) - The new compounds will provide a "full time" protection of neurons against aging and degeneration. Continuous administration technologies, which are one of the core competencies of Axxonis Pharma AG, will additionally enable the concept of 24 hours protection. (...) |
| 2007-12-17: |
Vasogen and Grupo Ferrer Announce Initial Roll - out of Celacade - New Therapy for Chronic Heart Failure
Mississauga, Canada ( PRN/ots ) - Vasogen Inc. ( NASDAQ:VSGN; TSX:VAS ) and Grupo Ferrer Internacional, S.A. ( "Ferrer" ), a leading European pharmaceutical and medical devices company, today announced the receipt of initial orders for Vasogen's Celacade( TM ) System in Germany. Celacade, a first - in - class therapy, is (...) |
| 2006-10-18: |
New Research Shows That Single Pill amlodipine besylate/atorvastatin calcium May Reduce 10 - Year Risk for a Heart Attack or Stroke by More Than 50 Percent
Fukuoka, Japan ( PRN/ots ) - - Therapy May Benefit Hypertensive Patients With Additional Risk Factors in Populations Across Asia and Latin America Single - pill amlodipine besylate/atorvastatin calcium ( Caduet( R ) ) may reduce the 10 - year risk of having a cardiovascular ( CV ) event - as determined (...) |
| 2004-11-19: |
Aplidin( R ) Granted Orphan Drug Status by the European Commission for the Treatment of Multiple Myeloma
Madrid, November 19 ( PRN/ots ) - PharmaMar announced today that Aplidin( R ) ( 1 ), its second marine - derived compound in clinical development, was granted orphan drug status by the European Commission for the treatment of multiple myeloma ( MM ) following adoption of a positive opinion by the Committee (...) |
| 2005-04-07: |
YONDELIS( R ) Granted Orphan Drug Designation by the U.S. FDA For The Treatment of Ovarian Cancer
Madrid, Spain ( PRN/ots ) - PharmaMar announced today that its marine - derived anti - cancer drug, YONDELIS( R ) ( trabectedin ), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration ( FDA ) for the treatment of ovarian cancer. The U.S. application sponsor, is Johnson & Johnson (...) |
| 2008-03-13: |
Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
Biocitech Park, Romainville, France ( PRN/ots ) - Cellectis SA ( NYSE: ALCLS ), a world leader in rational genome engineering, has announced today that it filed a patent infringement lawsuit against Precision BioSciences, Inc. in the United States District Court for the Eastern District of North (...) |
| 2006-10-11: |
Bristol - Myers Squibb Medical Imaging Receives European Commission Marketing Authorisation for Its Ultrasound Contrast Agent LUMINITY( TM ) ( perflutren lipid microsphere )
N. Billerica, Massachusetts ( PRN/ots ) - Bristol - Myers Squibb Medical Imaging announced today that the European Commission has granted marketing authorisation for LUMINITY( TM ), an ultrasound contrast agent, for use in patients with suboptimal echocardiograms who have suspected or established coronary artery disease.( 1 ) "With LUMINITY, (...) |
| 2008-09-03: |
GNC Continues European Expansion Through Exclusive Online Distribution Agreement with Active Nutrition International for Sales of Sports Nutrition Products in Sweden, Finland, Denmark & Norway
Pittsburgh ( PRN/ots ) - General Nutrition Centers, Inc., the largest global specialty retailer of nutritional supplements, today announced another step in its continuing expansion in Europe through an exclusive distribution agreement for online sales of GNC's private label products, its first in Europe, in (...) |
| 2005-12-12: |
PharmaMar Reports Positive Phase II Results on Aplidin( R ) in Patients With Advanced Multiple Myeloma at ASH
Madrid ( PRN/ots ) - PharmaMar today announces the results of the Aplidin( R ) Phase II trial which were presented at the American Society of Hematology 47th Annual Meeting in Atlanta, Georgia, USA, on Sunday 11 December. Aplidin reached its objective of overall response rate established in (...) |
| 2011-04-04: |
Miltenyi Biotec is picking up good VYBrations / New flow cytometer MACSQuant® VYB opens up novel avenues in cell analysis
Orlando, Florida ( na Originaltextservice ) - Miltenyi Biotec today announces the worldwide release and availability of the MACSQuant® VYB, a compact, benchtop flow cytometer featuring violet, yellow, and blue lasers, and detection of 10 optical parameters. The MACSQuant VYB enables easy but sophisticated (...) |
| 2008-11-20: |
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Cork, Ireland, November 20 ( PRN/ots ) - - Nearly 90 Percent of Patients Achieve Undetectable Viral Load in Phase IIa Trial Within 28 Days of Combined Treatment With Standard of Care New clinical data demonstrate the safety and antiviral activity of TMC435, an investigational (...) |
| 2009-09-21: |
Abbott's XIENCE V( R ) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long - Term Safety Results in SPIRIT III Trial
San Francisco ( PRN/ots ) - - Market - Leading XIENCE V Demonstrates Single - Digit Rate of Major Adverse Cardiac Events ( MACE ) at Three Years and a 43 Percent Reduction vs. TAXUS - No Additional Stent Thrombosis between Two and Three Years, and Impressive Low Rate of (...) |
| 2007-09-26: |
Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
Boxmeer, The Netherlands and London ( PRN/ots ) - Nobilon International B.V., part of Organon, the human health care business unit of Akzo Nobel, and Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announced that Nobilon has licensed Protherics' CoVaccine HT( TM ) adjuvant (...) |
| 2010-03-17: |
Agendia to Play Pivotal Role in ISPY - 2 Trial for Breast Cancer
HUNTINGTON BEACH, California and AMSTERDAM, March 17, 2010 ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I - SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research (...) |
| 2007-07-25: |
New SPIRIVA( R ) Respimat( R ) Inhaler Completes European Approval Process for COPD
Ingelheim, Germany ( PRN/ots ) - - Patients to Benefit From Easy - to - Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market SPIRIVA( R ) Respimat( R ) in the European Union for people with chronic obstructive (...) |
| 2008-03-31: |
First Statin Monotherapy to Achieve Regression of Coronary Atherosclerosis by Angiography in a Major Clinical Study
London ( PRN/ots ) - CRESTOR( TM ) ( rosuvastatin ) is the only statin to show regression of coronary atherosclerosis in a major clinical study. That result, which was based on intravascular ultrasound ( IVUS ) data from the ASTEROID study, has now been expanded upon by quantitative coronary angiography ( QCA ) (...) |
| 2009-07-02: |
FDA Approves Multaq( R ) for Patients With Atrial Fibrillation or Atrial Flutter
Paris ( PRN/ots ) - - Multaq( R ) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter - U.S Commercial Launch Planned for the Summer of 2009 Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today that the U.S. Food (...) |
| 2007-08-24: |
Avastin Approved in Europe for First - line Treatment of Patients With Advanced Lung Cancer
Basel, Switzerland ( PRN/ots ) - - First Medicine Shown to Extend Survival Beyond One Year in Previously Untreated Lung Cancer Patients Avastin ( bevacizumab ), Roche's innovative anti - cancer drug, was approved today in Europe for the first - line treatment of patients with advanced non - small (...) |
| 2011-03-10: |
Nordion Reports First Quarter 2011 Financial Results
Ottawa ( PRN/ots ) - Highlights: - Extended sales contract with major customer Lantheus Medical Imaging until 2013 - Announced return of cash to shareholders through dividend and Normal Course Issuer Bid ( NCIB ) - Achieved cost savings following completion of strategic repositioning Nordion (...) |
|
|
back...
1
2
3
4
5
6
7
8
9
10
11
more... |
